Author

Jason Steenkamp

Observed names: J. Steenkamp, Steenkamp, Jason

Institution: EVERSANA (Canada)

Observed institution: EVERSANA (Canada)

ORCID: 0009-0006-0685-069X

Observed ORCID: 0009-0006-0685-069X

OpenAlex ID: A5073715431

Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison

2022 · Andrew Menzies-Gow, Jason Steenkamp, et al. · Journal of Medical Economics · 55

Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus

2022 · Ian N Bruce, Sarowar Golam, et al. · Journal of Comparative Effectiveness Research · 29

Comparative efficacy and safety of tislelizumab and other programmed cell death protein 1 inhibitors in first-line treatment of advanced gastroesophageal cancers: a systematic review and network meta-analysis

2025 · Jaffer A. Ajani, Maria Alsina, et al. · Gastric Cancer · 5

Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B

2023 · Benoit Guillet, Songkai Yan, et al. · Advances in Therapy · 5

Indirect Treatment Comparison of Tezepelumab Versus Other Biologics in Severe Chronic Rhinosinusitis with Nasal Polyps: A Systematic Literature Review and Network Meta-analysis

2026 · Joseph K. Han, Joaquim Mullol, et al. · Advances in Therapy · 1

Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus

2022 · Ian N Bruce, Sarowar Golam, et al. · Journal of Comparative Effectiveness Research · 1

Methodological concerns and data discrepancies in the indirect treatment comparison of belimumab and anifrolumab

2026 · Kai Wai Lee, Becky Hooper, et al. · Zeitschrift für Rheumatologie

Msr204 Accounting for Differences in Maintenance Study Designs: Methodological Considerations for Nma

2026 · Becky Hooper, Elizabeth Salvo-Halloran, et al. · Value in Health

Supplementary data: Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment

2026 · Kulasekararaj, Austin, Scheinberg, Phillip, et al. · Figshare

Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment

2026 · Austin Kulasekararaj, Phillip Scheinberg, et al. · Journal of Comparative Effectiveness Research

Tislelizumab efficacy and safety compared to other anti–PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma

2026 · Jaffer A. Ajani, Elizabeth Smyth, et al. · Frontiers in Immunology

CO58 Comparative Efficacy of Iptacopan Monotherapy vs. Danicopan Add-on to C5i in Paroxysmal Nocturnal Hemoglobinuria (PNH) Results From an Indirect Treatment Comparison (ITC)

2025 · Phillip Scheinberg, Austin Kulasekararaj, et al. · Value in Health

PCR39 Health State Utility Values for Patients With Paroxysmal Nocturnal Hemoglobinuria Using EQ-5D-5L

2024 · P. Wang, J. Steenkamp, et al. · Value in Health

PB0692 Matching-Adjusted Indirect Comparison of rIX-FP versus rFIXFc for Prophylactic Treatment of Hemophilia B

2023 · S. Yan, B. Hooper, et al. · Research and Practice in Thrombosis and Haemostasis

Works count: 17

Citation count: 96

H-index: 4

I10-index: 2